Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextromethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.98 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.98 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.98 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.98 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.98 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.98 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | TACR1 | P25103 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextromethorphan SCHEMBL4882308 | 0.99 | CYP3A4 (0.98) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextromethorphan SCHEMBL570724 | 0.99 | CYP2D6 (0.96) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL7380035 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20808854 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20809259 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL248575 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL22722074 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL21095577 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL12091342 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL503864 | 0.99 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115616104-B | Dextromethorphan hydrochloride injection of medetomidine method for detecting liquid enantiomer | 山西远扬医药科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118475347-A | Combinations of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and norepinephrine reuptake inhibitors for the treatment of sleep apnea | 拜耳公司 | 2024-08-09 | — | — | CN | claimed |
| CN-116211830-A | Preparation method of sustained-release capsule of dextromethorphan hydrochloride | 宜昌人福药业有限责任公司 | 2023-06-06 | — | — | CN | claimed |
| CN-112999350-A | Pharmaceutical composition, compound preparation, and preparation method and application thereof | 北京斯利安药业有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-1476140-B1 | TASTE-MASKED FILM-TYPE OR WAFER-TYPE MEDICINAL PREPARATION | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2018-04-04 | — | — | EP | claimed |
| US-20130225627-A1 | DEXTROMETHORPHAN ANTITUSSIVE COMPOSITIONS | TRINITY LABORATORIES, INC. (TX) | 2013-08-29 | — | — | US | claimed |
| WO-2012018742-A2 | DEXTROMETHORPHAN ANTITUSSIVE COMPOSITIONS | TRINITY LABORATORIES, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| US-8017623-B2 | Dextromethorphan hydrochloride | TRINITY LABORATORIES, INC. (US) | 2011-09-13 | — | — | US | claimed |
| US-20100004278-A1 | DEXTROMETHORPHAN HYDROCHLORIDE | LUMINUS BIOSCIENCES, INC. | 2010-01-07 | — | — | US | claimed |
| US-7407669-B2 | Fast dissolving orally consumable films | MCNEIL-PPC, INC. (US) | 2008-08-05 | — | — | US | claimed |
| CN-1830442-A | Compound formula dextro methaphen oral disintegration tablet and its preparation method | SHENZHEN PHARMACEUTICAL FACTOR (CN) | 2006-09-13 | — | — | CN | claimed |
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | claimed |
| WO-2005048980-A1 | COMPOSITION FOR ORAL CONSUMABLE FILM | KBP CO., LTD (KR) | 2005-06-02 | — | — | WO | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| JP-11225791-A | — | — | None | — | — | JP | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-5037823-A | Administering ibuprofen, hydrochlorothiazide and an anti-histamine | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| US-4888343-A | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | BRISTOL-MYERS COMPANY (US) | 1989-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | GRIN2A 778/4885SIGMAR1 1118/4885GRIN1 554/4885 |
| US-20100004278-A1 | DEXTROMETHORPHAN HYDROCHLORIDE | CYP3A43, CYP2D6, CYP3A5 | GRIN2A 196/4885SIGMAR1 34/4885GRIN1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.